Saturday, July 5, 2025 7/5/2025

Evaluation of drug mixtures for treating pain: behavioral and pharmacological interactions between opioids and serotonin agonists

Award Number: R01DA046532
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2019
PERIOD OF PERFORMANCE END DATE: 11/30/2024

Group Awards By:

View Award Description

Evaluation of drug mixtures for treating pain: behavioral and pharmacological interactions between opioids and serotonin agonists - PROJECT SUMMARY Opioids remain the gold standard for treating moderate to severe pain, but their use is limited by numerous adverse effects including tolerance, dependence, abuse, and overdose. Adverse effects could be avoided by combining an opioid with another drug, such that smaller doses of the opioid (in combination with another drug) produce the desired therapeutic effect. Direct-acting serotonin type 2 (5-HT2) receptor agonists interact in a synergistic manner with the opioid morphine to produce antinociceptive effects, suggesting a 5-HT2 receptor agonist could be combined with small dose of an opioid to treat pain thereby lowering the risk associated with larger doses. However, little is known about interactions between 5-HT2 receptor agonists and other opioids, and it is unclear whether 5-HT2 receptor agonists enhance other adverse effects, particularly those relating to abuse or overdose or alter the consequences of repeated treatment with an opioid. Proposed studies evaluate the therapeutic potential of mixtures of opioids and 5-HT2 receptor agonists using highly translatable and well- established procedures to characterize the antinociceptive, respiratory-depressant (overdose), positive- reinforcing (abuse), and discriminative-stimulus (subjective) effects of drug mixtures as well as the impact of chronic treatment on the development of tolerance to and physical dependence on opioids. Studies in Aim 1 characterize acute interactions between opioids and 5-HT2 receptor agonists for antinociceptive effects and examine the contribution of 5-HT2 receptor subtypes. Studies in Aim 2 evaluate the acute respiratory- depressant, positive reinforcing, and discriminative stimulus effects of mixtures containing an opioid and a 5- HT2 receptor agonist. Studies in Aim 3 compare effects of daily dosing with a mixture of an opioid and a 5-HT2 receptor agonist to those of the opioid administered alone in order to evaluate changes in the development of tolerance and physical dependence. These studies will identify combinations of opioids and 5-HT2 receptor agonists that increase the therapeutic window of opioids by decreasing the dose of opioid necessary for therapeutic effects, while also reducing the adverse effects that currently limit the legitimate medical use of opioids (tolerance, dependence, abuse and overdose) and 5-HT2 receptor agonists (subjective effects). Using a species and procedures that are highly translatable to humans, these studies will provide proof-of-concept for this innovative approach to pain treatment and evaluate the utility of targeting 5-HT receptors for analgesic drug development.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Drug Use and Addiction Research Programs	000	5	4/23/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $383,028 )
2023	2023	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER OF SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Drug Use and Addiction Research Programs	000	5	11/8/2022	NON-COMPETING CONTINUATION	$383,028
														Subtotal = $383,028

Issue Date FY: 2022 ( Subtotal = $446,628 )
2022	2022	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER OF SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Drug Use and Addiction Research Programs	001	4	11/30/2021	NON-COMPETING CONTINUATION	$44,664
2022	2022	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER OF SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Drug Use and Addiction Research Programs	000	4	11/8/2021	NON-COMPETING CONTINUATION	$401,964
														Subtotal = $446,628

Issue Date FY: 2021 ( Subtotal = $404,601 )
2021	2021	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER OF SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Drug Use and Addiction Research Programs	001	3	3/3/2021	NON-COMPETING CONTINUATION	$40,461
2021	2021	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER OF SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Drug Use and Addiction Research Programs	000	3	10/30/2020	NON-COMPETING CONTINUATION	$364,140
														Subtotal = $404,601

Issue Date FY: 2020 ( Subtotal = $408,801 )
2020	2020	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER OF SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Drug Use and Addiction Research Programs	001	2	2/11/2020	NON-COMPETING CONTINUATION	$40,881
2020	2020	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER OF SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Drug Use and Addiction Research Programs	000	2	12/10/2019	NON-COMPETING CONTINUATION	$367,920
														Subtotal = $408,801

Issue Date FY: 2019 ( Subtotal = $449,232 )
2019	2019	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER OF SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Drug Use and Addiction Research Programs	000	1	1/21/2019	NEW	$449,232
														Subtotal = $449,232

Grand Total All Awards = $2,092,290

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Evaluation of drug mixtures for treating pain: behavioral and pharmacological interactions between opioids and serotonin agonists

Award Number: R01DA046532

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2019

PERIOD OF PERFORMANCE END DATE: 11/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer